Catalent Inc (CTLT) Stock Fundamental Analysis
NYSE:CTLT - New York Stock Exchange, Inc. - US1488061029 - Common Stock - Currency: USD
Overall CTLT gets a fundamental rating of 3 out of 10. We evaluated CTLT against 195 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of CTLT have multiple concerns. CTLT has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year CTLT was profitable.
CTLT had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: CTLT reported negative net income in multiple years.
In the past 5 years CTLT always reported a positive cash flow from operatings.
1.2 Ratios
CTLT has a Return On Assets of -4.25%. This is in the better half of the industry: CTLT outperforms 78.01% of its industry peers.
The Return On Equity of CTLT (-11.66%) is better than 75.92% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.25% | ||
| ROE | -11.66% | ||
| ROIC | N/A |
ROA(3y)-2.82%
ROA(5y)-0.09%
ROE(3y)-8.14%
ROE(5y)-1.42%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CTLT has a Gross Margin of 21.82%. This is comparable to the rest of the industry: CTLT outperforms 51.83% of its industry peers.
In the last couple of years the Gross Margin of CTLT has declined.
The Profit Margin and Operating Margin are not available for CTLT so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 21.82% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-13.68%
GM growth 5Y-7.41%
2. Health
2.1 Basic Checks
CTLT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CTLT has more shares outstanding
Compared to 5 years ago, CTLT has more shares outstanding
CTLT has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of 1.62, we must say that CTLT is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.62, CTLT is in the better half of the industry, outperforming 64.92% of the companies in the same industry.
CTLT has a debt to FCF ratio of 49.84. This is a negative value and a sign of low solvency as CTLT would need 49.84 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 49.84, CTLT is in the better half of the industry, outperforming 78.01% of the companies in the same industry.
A Debt/Equity ratio of 1.38 is on the high side and indicates that CTLT has dependencies on debt financing.
CTLT has a Debt to Equity ratio of 1.38. This is in the lower half of the industry: CTLT underperforms 74.87% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.38 | ||
| Debt/FCF | 49.84 | ||
| Altman-Z | 1.62 |
ROIC/WACCN/A
WACC9.31%
2.3 Liquidity
A Current Ratio of 2.51 indicates that CTLT has no problem at all paying its short term obligations.
CTLT has a Current ratio (2.51) which is in line with its industry peers.
CTLT has a Quick Ratio of 1.93. This is a normal value and indicates that CTLT is financially healthy and should not expect problems in meeting its short term obligations.
CTLT has a Quick ratio of 1.93. This is comparable to the rest of the industry: CTLT outperforms 44.50% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.51 | ||
| Quick Ratio | 1.93 |
3. Growth
3.1 Past
The earnings per share for CTLT have decreased strongly by -61.40% in the last year.
The earnings per share for CTLT have been decreasing by -33.48% on average. This is quite bad
The Revenue has been growing slightly by 4.71% in the past year.
The Revenue has been growing by 11.71% on average over the past years. This is quite good.
EPS 1Y (TTM)-61.4%
EPS 3Y-56.51%
EPS 5Y-33.48%
EPS Q2Q%-30%
Revenue 1Y (TTM)4.71%
Revenue growth 3Y3.1%
Revenue growth 5Y11.71%
Sales Q2Q%4.18%
3.2 Future
The Earnings Per Share is expected to grow by 73.38% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 7.44% on average over the next years.
EPS Next Y350.55%
EPS Next 2Y148.11%
EPS Next 3Y113.64%
EPS Next 5Y73.38%
Revenue Next Year8.33%
Revenue Next 2Y8.2%
Revenue Next 3Y8.33%
Revenue Next 5Y7.44%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 288.55, CTLT can be considered very expensive at the moment.
Based on the Price/Earnings ratio, CTLT is valued a bit cheaper than the industry average as 78.01% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 27.30, CTLT is valued quite expensively.
With a Price/Forward Earnings ratio of 41.25, CTLT can be considered very expensive at the moment.
Based on the Price/Forward Earnings ratio, CTLT is valued a bit cheaper than the industry average as 76.44% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 21.76, CTLT is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 288.55 | ||
| Fwd PE | 41.25 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CTLT indicates a somewhat cheap valuation: CTLT is cheaper than 76.96% of the companies listed in the same industry.
78.53% of the companies in the same industry are more expensive than CTLT, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 116.39 | ||
| EV/EBITDA | 36.47 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
CTLT's earnings are expected to grow with 113.64% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.82
PEG (5Y)N/A
EPS Next 2Y148.11%
EPS Next 3Y113.64%
5. Dividend
5.1 Amount
CTLT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
63.48
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners92.2%
Inst Owner Change0%
Ins Owners0.48%
Ins Owner Change0%
Market Cap11.52B
Analysts52.86
Price Target64.77 (2.03%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-149.78%
Min EPS beat(2)-336.02%
Max EPS beat(2)36.46%
EPS beat(4)1
Avg EPS beat(4)-365.14%
Min EPS beat(4)-1032.86%
Max EPS beat(4)36.46%
EPS beat(8)2
Avg EPS beat(8)-208.81%
EPS beat(12)5
Avg EPS beat(12)-141.22%
EPS beat(16)9
Avg EPS beat(16)-103.51%
Revenue beat(2)1
Avg Revenue beat(2)-0.51%
Min Revenue beat(2)-5.19%
Max Revenue beat(2)4.16%
Revenue beat(4)1
Avg Revenue beat(4)-1.79%
Min Revenue beat(4)-6.04%
Max Revenue beat(4)4.16%
Revenue beat(8)4
Avg Revenue beat(8)0.21%
Revenue beat(12)6
Avg Revenue beat(12)-0.33%
Revenue beat(16)8
Avg Revenue beat(16)-0.03%
PT rev (1m)0.11%
PT rev (3m)4.53%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-43.12%
EPS NY rev (1m)4.18%
EPS NY rev (3m)-6.02%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.9%
Revenue NY rev (1m)-0.08%
Revenue NY rev (3m)-0.69%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 288.55 | ||
| Fwd PE | 41.25 | ||
| P/S | 2.61 | ||
| P/FCF | 116.39 | ||
| P/OCF | 28.88 | ||
| P/B | 3.25 | ||
| P/tB | 31.57 | ||
| EV/EBITDA | 36.47 |
EPS(TTM)0.22
EY0.35%
EPS(NY)1.54
Fwd EY2.42%
FCF(TTM)0.55
FCFY0.86%
OCF(TTM)2.2
OCFY3.46%
SpS24.36
BVpS19.51
TBVpS2.01
PEG (NY)0.82
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.25% | ||
| ROE | -11.66% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 21.82% | ||
| FCFM | 2.24% |
ROA(3y)-2.82%
ROA(5y)-0.09%
ROE(3y)-8.14%
ROE(5y)-1.42%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-13.68%
GM growth 5Y-7.41%
F-Score5
Asset Turnover0.46
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.38 | ||
| Debt/FCF | 49.84 | ||
| Debt/EBITDA | 11.05 | ||
| Cap/Depr | 61.22% | ||
| Cap/Sales | 6.78% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 90.27% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.51 | ||
| Quick Ratio | 1.93 | ||
| Altman-Z | 1.62 |
F-Score5
WACC9.31%
ROIC/WACCN/A
Cap/Depr(3y)125.99%
Cap/Depr(5y)159.79%
Cap/Sales(3y)11.57%
Cap/Sales(5y)13.39%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-61.4%
EPS 3Y-56.51%
EPS 5Y-33.48%
EPS Q2Q%-30%
EPS Next Y350.55%
EPS Next 2Y148.11%
EPS Next 3Y113.64%
EPS Next 5Y73.38%
Revenue 1Y (TTM)4.71%
Revenue growth 3Y3.1%
Revenue growth 5Y11.71%
Sales Q2Q%4.18%
Revenue Next Year8.33%
Revenue Next 2Y8.2%
Revenue Next 3Y8.33%
Revenue Next 5Y7.44%
EBIT growth 1Y-166.67%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year196.68%
EBIT Next 3Y58.17%
EBIT Next 5Y41.23%
FCF growth 1Y121.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y116.85%
OCF growth 3Y-14.78%
OCF growth 5Y1.59%